Edition:
Deutschland

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

38.77EUR
14 Aug 2020
Change (% chg)

€-0.35 (-0.89%)
Prev Close
€39.12
Open
€39.07
Day's High
€39.18
Day's Low
€38.61
Volume
1,315,217
Avg. Vol
1,877,019
52-wk High
€51.54
52-wk Low
€24.25

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Buy/Sell

Sell Hold Buy
1.87 Mean rating from 23 analysts

Overall

Beta: 1.00
Market Cap(Mil.): €21,808.11
Shares Outstanding(Mil.): 557.47
Dividend: 0.84
Yield (%): 2.17

UPDATE 3-Fresenius cuts 2020 outlook on pandemic impact

* Shares down 4% (Adds details from conference call, updates shares)

Fresenius Medical Care reports second-quarter beat as pandemic effects ease

German dialysis specialist Fresenius Medical Care beat second-quarter net income expectations on Thursday, citing lower negative impact of the coronavirus pandemic compared to the previous quarter and strong underlying business performance.

Fresenius Medical Care reports Q2 beat as pandemic effects ease

July 30 German dialysis specialist Fresenius Medical Care beat second-quarter net income expectations on Thursday, citing lower negative impact of the coronavirus pandemic compared to the previous quarter and strong underlying business performance.

FACTBOX-Drugmakers rush to develop COVID-19 treatments

(Updates Gilead, Roche, Regeneron) July 29 Drugmakers around the world are rushing to develop treatments for COVID-19, the fast-spreading respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Gilead Sciences Inc's remdesivir is at the forefront of the efforts to treat the disease, after it helped shorten hospital recovery times in a clinical trial. The following is a list of major companies that are developing treatments. For a separate F

U.S. demand outstripping supply of steroid treatment for COVID

NEW YORK, June 25 Soaring hospital demand for the steroid dexamethasone, which British researchers say significantly reduces mortality among severely ill COVID-19 patients, is outstripping supply of the drug, but hospitals have so far been able to treat patients out of their inventories, according to Vizient Inc, a drug buyer for about half of U.S. hospitals.

BRIEF-Fresenius Appoints Sebastian Biedenkopf As Chief Legal And Compliance Officer

* SEBASTIAN BIEDENKOPF, CURRENTLY GENERAL COUNSEL OF ROBERT BOSCH GMBH, WILL JOIN THE MANAGEMENT BOARD OF FRESENIUS AS CHIEF LEGAL AND COMPLIANCE OFFICER

UPDATE 1-Asian pharma stocks jump on hopes for steroid in COVID-19 treatment

TOKYO/BENGALURU/KARACHI, June 17 Shares in Asian generic drug firms that make the anti-inflammatory steroid dexamethasone jumped on Wednesday after a trial showed it helped reduce death in severe COVID-19 cases.

BRIEF-German Cartel Office Approves Helios Acquisition Of Malteser Hospital In Bonn

* IT APPROVES HELIOS ACQUISITION OF MALTESER HOSPITAL IN BONN Further company coverage: (Berlin Speed Desk)

Japan's Nichi-Iko jumps on hopes for steroid sales boost to treat COVID-19

TOKYO, June 17 Shares in Japanese generic drug maker Nichi-Iko Pharmaceutical Co, whose products include steroid drug dexamethasone, jumped nearly 5% on Wednesday after trial results showed it helped reduce death rates of COVID-19 patients.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.32%
Rohstoffe -0.07%
Industrie -0.11%
Konjunktur abhängige Waren & Dienstleistungen -0.09%
Konjunktur unabhängige Waren & Dienstleistungen +0.04%
Finanzindustrie -0.32%
Pharma -0.19%
Technologie +0.19%
Telekommunikation -0.84%